Nicholas Brousseau

Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada

Danuta M. Skowronski, Yossi Febriani, Solmaz Setayeshgar et al. · Clinical Infectious Diseases · 2022 · 135 citations · Full text

Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study

Sara Carazo, Danuta M. Skowronski, Marc Brisson et al. · The Lancet Infectious Diseases · 2022 · 121 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +8

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

Alexandra Tauzin, Shang Yu Gong, Guillaume Beaudoin-Bussières et al. · Cell Host & Microbe · 2021 · 111 citations · Full text

Vaccination, Vaccine Development, Sars-cov-2 Spike +9

Higher Risk of Measles When the First Dose of a 2-Dose Schedule of Measles Vaccine Is Given at 12–14 Months Versus 15 Months of Age

Gaston De Serres, Nicole Boulianne, Fannie Defay et al. · Clinical Infectious Diseases · 2012 · 92 citations

Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada

Danuta M. Skowronski, Solmaz Setayeshgar, Yossi Febriani et al. · 2021 · 60 citations · Full text

Vaccination, Vaccine Safety, Age Group +11